Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Maurille Feudjo Tepie"'
Autor:
Sajan Khosla, Mark J Nagy, Johan Liwing, Michael J Seewald, George Kafatos, Maurille Feudjo Tepie, Stephanie Marchese
Publikováno v:
Therapeutic Innovation & Regulatory Science
In the new era of healthcare digitalization, there is a golden opportunity in the overlap between digital health and Real-World Evidence (RWE). In this commentary, we define RWE and digital health and investigate their intersection. We describe the s
Autor:
Jonathan M Plumb, Mark J Nagy, Robert J. LoCasale, Donald Yin, Sajan Khosla, Ben Gutierrez, Mette Hammer, Chris L Pashos, Michael J Seewald, Maurille Feudjo Tepie, Johan Liwing
Publikováno v:
Journal of Comparative Effectiveness Research. 9:155-159
This White Paper is authored by 11 industry real-world evidence (RWE) experts, with support from IQVIA, as part of the ‘RWE Leadership Forum’: a group of industry leaders who come together as noncompetitive partners to understand and respond to i
Publikováno v:
Osteoporosis International
Summary Gaining full benefits from osteoporosis medications requires long-term treatment. Investigating the real-world persistence of women receiving osteoporosis medications in the UK, we found that most patients stop treatment within a year. To pre
Autor:
Alan Calleja, Toby Collins, Ben Gutierrez, Michael J Seewald, Maurille Feudjo Tepie, Johan Liwing, Nancy A Dreyer, Chris L Pashos, Sajan Khosla, Robert J. LoCasale, Jonathan M Plumb
Publikováno v:
Ther Innov Regul Sci
Therapeutic Innovation & Regulatory Science
Therapeutic Innovation & Regulatory Science
This commentary is authored by several industry real-world evidence (RWE) experts, with support from IQVIA, as part of the 'RWE Leadership Forum': a group of Industry Leaders who have come together as non-competitive partners to understand and respon
Autor:
Sabada Dube, Gaston Demonty, Marjorie Leclerc, Peter Burdon, Siegfried Segaert, George Kafatos, Alain Flinois, Maurille Feudjo-Tepie, Kimberley Lowe
Publikováno v:
Clinical colorectal cancer. 19(2)
Introduction This study aimed to provide a description of existing measures for the prevention and management of epidermal growth factor receptor inhibitor monoclonal antibody-induced skin toxicities and factors impacting patients’ adherence to tho
Autor:
Anna Spångeus, Kristina Åkesson, Oskar Ström, Maurille Feudjo-Tepie, Rosa Lauppe, G. Ortsater, Östen Ljunggren
Publikováno v:
Archives of Osteoporosis. 14
This study assesses the impact of risk factors for fracture in women aged 80+ and 60–79. The results suggest that risk assessment which fits younger women may not be suited for the 80+ strata as many common risk factors are less predictive in the o
Autor:
Johan Liwing, Sajan Khosla, Alan Calleja, Toby Collins, Michael J Seewald, Maurille Feudjo Tepie, Robert J. LoCasale, Chris L Pashos, Jonathan M Plumb, Ben Gutierrez, Nancy A Dreyer
Publikováno v:
Therapeutic Innovation & Regulatory Science. 55:97-97
The article Bridging the Gap Between RCTs and RWE Through Endpoint Selection, written by Robert J. LoCasale, Chris L. Pashos, Ben Gutierrez, Nancy A. Dreyer, Toby Collins, Alan Calleja, Michael J. Seewald, Jonathan M. Plumb, Johan Liwing, Maurille Fe
Autor:
Leslie Spangler, Cathy W. Critchlow, Mazhar Iqbal, A. Taylor, J. Bayly, Andrew Roddam, Samara Ferguson, Maurille Feudjo Tepie
Publikováno v:
Journal of Evaluation in Clinical Practice. 22:31-39
Rationale, aims and objectives Clinical trial data suggest that patients who have received bisphosphonates continue to benefit from them after discontinuation. However, data from real-world clinical practice are inconclusive. We assessed the impact o
Autor:
L. Karlsson, Oskar Ström, Jetty Overbeek, Maurille Feudjo Tepie, M. Intorcia, Johan Mesterton
Publikováno v:
Archives of Osteoporosis
Summary Using Swedish and Dutch registry data for women initiating bisphosphonates, we evaluated two methods of comparing the real-world effectiveness of osteoporosis treatments that attempt to adjust for differences in patient baseline characteristi
Publikováno v:
Menopause. 21:1106-1113
This study aims to describe the switch patterns of osteoporosis medication in postmenopausal women and to explore the impact of switching on persistence.This study used a cohort of postmenopausal women who initiated the first treatment with osteoporo